Alkali Metals Limited
ALKALI · NSE · Basic Materials
StocksWizard rates Alkali Metals Limited a Hold, scoring 45/100 on our blended model. At ₹86.16 it trades above our blended DCF and relative-multiples fair value of ₹77.11, implying roughly 11% downside to that estimate — we read the stock as fairly valued. Financial health scores 53/100 (grade C). It clears 4 of 11 investability checks, with durability 31, valuation 27 and momentum 91 on our 0–100 scales.
These are StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹61.69. Low-confidence estimate — limited data.
Investability checklist
- ✕ROE above 15%1.2%
- ✓Low debt (D/E < 0.5)0.41x
- ✕Positive free cash flow
- ✓Revenue growth > 10%16%
- ✕Earnings growing-8%
- ✕Net margin ≥ 10%0.6%
- ✕Current ratio > 1.51.13
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- –Altman Z in safe zone
- –Piotroski ≥ 7
1-year price
EOD · 2026-06-19Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Weaknesses
- •Low return on equity (1.2%).
Opportunities
- •Revenue growing (16% YoY).
Threats
- •Earnings contracting year on year.
- •Rich valuation versus sector peers.
About Alkali Metals Limited
Alkali Metals Limited manufactures and sells chemicals in India and internationally. The company offers API products, including benzocaine, fluconazole, loperamide hydrochloride, losartan potassium, metformin hydrochloride, phenylephrine hydrochloride, and rabeprazole sodium. It also provides pyridine, acetylpyridine, alkyl borate, aminopyridine, bipyridine, bromopyridine, chloropyridine, cyanopyridine, cyclic, diethylamino pyridine, ethoxypyridine, fluoropyridine, hydroxypyr
More in Basic Materials
All stocksOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.